Quick Answer
Allarity Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $14.69 million for the year ending 2025.
- Allarity Therapeutics, Inc. showed a decrease of -24.8% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Allarity Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2022 to 2025 (4 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2019: $1.52 million | Q3 2020: $30.0 thousand | Q4 2020: $298.0 thousand | Q3 2021: $5.58 million | Q2 2022: $7.68 million | Q3 2022: $3.95 million | Q1 2023: $295.0 thousand | Q2 2023: $420.0 thousand | Q3 2023: $1.40 million | Q1 2024: $312.0 thousand | Q2 2024: $19.23 million | Q1 2025: $25.20 million | Q2 2025: $17.80 million | Q3 2025: $16.90 million.
- Over the full 4 years of available data (2022 to 2025), Allarity Therapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 623.9%.
- Historical annual values: Fiscal year 2025: $14.69 million | Fiscal year 2024: $19.53 million | Fiscal year 2023: $166.0 thousand | Fiscal year 2022: $2.03 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: